Page 64 - Clinical Development News Today

/PRNewswire/ -- The "Vancomycin Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report provides...

OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McKune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at PPD, part of Thermo Fisher. They answered some pertinent questions surrounding rare diseases.

The Pistoia Alliance is a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D. It has just announced its four new strategic priorities made up of global pharma and tech representatives to deliver new project ideas to drive industry change.

Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.

The first and only enzyme replacement therapy for the treatment of a very rare and complex blood disorder has been approved by the US Food and Drug Administration.

A step forward has been taken toward a cure for a common and distressing skin condition after Novartis announced positive data from a clinical trial.

Celadon Pharmaceuticals announced today (November 16) that it has secured a new sales contract with an unnamed European medical cannabis company.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call. Please note that today’s event is being recorded. At this time, all participants are in a listen-only mode. Instructions for the question-and-answer session will follow after the prepared remarks. […]

Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 13, 2023--